Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID... see more

Opinion & Analysis (NDAQ:NVAX)

    Morning Market Outlook for May 10, 2024

    TheUpTrend May 10, 2024

    Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

    Streetwise Reports May 27, 2020

    Novavax Announces Its First-in-Human Coronavirus Vaccine Trial Will Begin in Mid-May

    Streetwise Reports April 9, 2020

    Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected

    Streetwise Reports December 27, 2018

    The inflammatory disease marketplace meets the drug pricing controversy: FBR & Co.'s Vernon Bernardino

    The Life Sciences Report October 22, 2015